id: NEW:multidrug_resistant_organisms_to_all_cause_mortality_rate
name: Multidrug-Resistant Organism Infection â†’ All-Cause Mortality Rate
from_node:
  node_id: NEW:multidrug_resistant_organisms
  node_name: Multidrug-Resistant Organism Infection
to_node:
  node_id: all_cause_mortality_rate
  node_name: All-Cause Mortality Rate
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Infection with multidrug-resistant organisms (MDROs) such as Acinetobacter
  baumannii, ESBL-producing Enterobacteriaceae, or MRSA establishes in critically
  ill patients'
- 'Step 2: Limited antibiotic treatment options due to resistance patterns lead to
  delayed effective antimicrobial therapy and treatment failures'
- 'Step 3: Prolonged infection duration results in sustained inflammatory response,
  progressive organ dysfunction, and sepsis complications'
- 'Step 4: Severe infections by MDR pathogens contribute to increased ICU length of
  stay, need for mechanical ventilation, and multi-organ failure'
- 'Step 5: Cumulative physiological stress and inadequate infection control result
  in elevated mortality rates'
evidence:
  quality_rating: C
  n_studies: 2
  primary_citation: 'R. M. Bateman et al. 2016. ''36th International Symposium on
    Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.''
    Critical care (London, England).'
  supporting_citations: []
description: Multidrug-resistant organism infections in ICU patients are associated
  with increased mortality through multiple mechanisms including treatment failures
  due to limited antibiotic options, prolonged infection duration, enhanced inflammatory
  responses, and progressive organ dysfunction. Studies from the symposium abstracts
  document MDRO epidemiology in various ICU settings (P075-P079) and demonstrate that
  infections caused by extensively drug-resistant bacteria, including gram-negative
  bacilli, are associated with adverse outcomes. The use of immunomodulatory therapy
  such as IgM-enriched immunoglobulins has shown potential to improve survival in
  these patients.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: ICU type and patient population
  direction: strengthens
  strength: moderate
  description: Surgical ICU patients and those with specific conditions (building
    construction exposure) may have higher MDRO infection rates
- name: Immunoglobulin therapy
  direction: weakens
  strength: moderate
  description: Treatment with polyclonal IgM-enriched immunoglobulins may improve
    outcomes in severe infections by MDR pathogens (P078)
- name: Prior antibiotic exposure
  direction: strengthens
  strength: moderate
  description: Previous antibiotic use increases risk of MDRO colonization and subsequent
    infection
